The short version
- A dedicated NHS clinic in Liverpool is treating over 100 referrals for ketamine-induced bladder damage among children as young as 13.
- Patients describe severe pain and tissue shedding, with some entering a cycle where they use the drug to manage symptoms caused by the drug itself.
- Experts note a lack of inpatient detox facilities for minors under 16, creating significant barriers to recovery despite rising usage rates.
Medical professionals at Alder Hey Hospital in Liverpool are responding to a sharp increase in severe urinary tract injuries among children linked to ketamine consumption. The facility operates the United Kingdom’s first and only National Health Service clinic specifically designed to treat this condition, which has seen a rapid escalation in referrals since its launch last May. Doctors report that patients as young as 13 are presenting with advanced damage, indicating that some individuals may have begun using the substance before age 12.
The physical toll of the drug is described by clinicians as devastating to the urinary system. Patients frequently report extreme pain during urination, comparing the sensation to passing broken glass. In severe cases, the protective lining of the bladder sheds, leading users to describe the experience as excreting a jellyfish-like substance. This condition, often referred to as ketamine bladder, affects the entire urinary tract and can result in blood-stained urine, incontinence, abdominal spasms, and potentially kidney failure if left untreated.
A particularly troubling aspect of this health crisis is the development of a self-perpetuating cycle of abuse. Because ketamine acts as a general anesthetic and potent pain reliever, some young users continue consuming the drug to numb the very pain it causes. Clinicians refer to this pattern as the 'K loop,' where the relief provided by the substance temporarily masks symptoms while simultaneously accelerating tissue degradation. This dynamic makes cessation difficult, even for those who recognize the severity of their physical decline.
The demographic affected by this trend often includes children with complex backgrounds. Many patients at the clinic have histories of emotional trauma, attention deficit hyperactivity disorder, or involvement with the care system. For some, the drug serves as a coping mechanism to quiet intrusive thoughts or manage anxiety. The accessibility and low cost of ketamine, described by experts as pocket-money level pricing, facilitate its spread among youth who may not have access to other forms of support or entertainment.
Data from the clinic illustrates the accelerating nature of the problem. In 2023, doctors treated a single young patient with these symptoms; that number rose to nine in 2024 before surging significantly in 2025. The volume of cases prompted the establishment of the specialized unit, which now receives approximately one referral per week from general practitioners and emergency departments across Cheshire, Merseyside, and surrounding regions. This trajectory suggests a broader public health issue extending beyond the immediate locality.
While cessation of use can sometimes reverse early-stage damage, severe cases may require surgical intervention, including bladder repair or removal. The British Association of Urological Surgeons estimates that roughly 30 percent of frequent ketamine users develop bladder issues. Although cannabis and alcohol remain more prevalent among young people, ketamine is increasingly viewed as a third-tier substance in terms of popularity, with many users experimenting with multiple substances simultaneously, complicating the clinical picture.
Systemic barriers to treatment remain a significant concern for medical staff. In the UK, individuals under the age of 16 are generally ineligible for inpatient detoxification stays, a service that would be available to adults. This disparity leaves vulnerable minors without access to intensive residential care, even when they express a desire to stop using drugs. Clinicians argue that this gap in services is inequitable and hinders recovery efforts for those ready to seek help.
The regulatory status of ketamine remains a point of contention. Despite calls to reclassify the substance as a Class A drug due to its harms, the Advisory Council on the Misuse of Drugs has recommended maintaining its current Class B status, similar to amphetamines and cannabis. As usage patterns evolve and health impacts become more visible, medical experts continue to advocate for improved resources and earlier intervention strategies to address the growing number of young people suffering from ketamine-related injuries.
Sources behind this briefing
Go to the original reporting
- BBC News↗Child ketamine users getting bladder damage describe 'peeing a jellyfish'
